Satsuma Pharmaceuticals Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Satsuma Pharmaceuticals Inc
Access all reports
Satsuma Pharmaceuticals Inc is a development-stage biopharmaceutical company focused on innovating therapeutic products for people suffering from migraine and other debilitating conditions. Its primary product candidate is STS101, a dihydroergotamine (DHE) nasal powder, aimed at offering a significant and differentiated treatment option for acute migraine attacks. Satsuma Pharmaceuticals is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
STSA
Country
🇺🇸 United States